Last updated on February 2019
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Brief description of study
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Clinical Study Identifier: NCT01442194
Start Over
Novartis Pharmaceuticals
Novartis Investigative Site Delray Beach, FL United States1.61miles
Connect »